Predictmedix Inc

Predictmedix — Investor Presentation (March 2022)

23 slides from Predictmedix's investor presentation, March 2022

  1. Slide 1: Predictmedix

    PREDICTMEDIX.COM CSE : PMED OTCQB : PMEDF

  2. Slide 2: Forward-looking statements and disclaimer

    Predictmedix Inc. (the ”Company”) is a reporting issuer under the Securities Exchange Act of 1934 (the “34 Act”). Further information about the Company is available at the SEC’s EDGAR website at: https://www.sec.gov/edgar/browse/?CIK=1878079&owner=exclude This presentation is qualified by the Compan

  3. Slide 3: Predictmedix

    Predictmedix Predictmedix is an emerging provider of rapid health screening, medical devices, and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a CSE: PMED - OTCQB: PMEDF proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiolo

  4. Slide 4: The Current Landscape

    The Current Landscape Triage Workplace Solution Infectious Cannabis & Mental & Diseases Alcohol Virtual Illnesses Impairment Care 4 CSE : PMED OTCQB : PMEDF

  5. Slide 5: Safe Entry Station

    SAFE ENTRY STATION SAFE ENTRY STATION TIMES MOST 2 INFLUENTIAL 2 PERSONALITIES ki Seer NYS) CSE: PMED OTCQB : PMEDF —)

  6. Slide 6: Infectious disease screening with Safe Entry Station

    Independent clinical study is currently underway at North Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and then make a determination as American Hospital to the probability of that person being infected or not infected. Real Clinical vali

  7. Slide 7: Cannabis and alcohol impairment screening

    Independent clinical study is currently Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired. underway at North Without the ability to determine impairment, it is impossible to accurately A

  8. Slide 8: Triage screening solution data collection

    The current method of collecting incoming patient data in hospital settings is cumbersome, time-consuming, and a nightmare for nurses and doctors. Data collection at Predictmedix is developing an AI powered Triage Screening multiple hospitals Solution to help Health Care Workers make quicker, import

  9. Slide 9: Mental illness diagnostic screening

    Predictmedix believes its technology may be expanded in the future to enable First Diagnostic Tool screening for certain mental illnesses. Mental illness is difficult to detect at early stages, primarily due to a lack of diagnostic tools other than standardized Predictmedix Mental Illness Diagnostic

  10. Slide 10: Clinical studies underway at North American Hospital

    Clinical studies underway at North Clinical studies are underway at a North American Hospital where Predictmedix’s infectious diseases and impairment detection American Hospital solutions are being clinically evaluated, fulfilling a prerequisite for certification with the U.S Food and Drug Administr

  11. Slide 11: Safe Entry Stations are CE Mark and ISO Certified

    Safe Entry Stations are CE Mark and ISO Certified The CE mark declares the conformity of the Safe Entry Station with EU regulations and indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. ISO 13485 is the medi

  12. Slide 12: Building value through AI-powered medical devices

    Building value through AI-powered Predictmedix’s R&D strategy focuses on developing AI-powered medical devices medical devices for healthcare, workplace, law enforcement, public spaces, and more. that can save lives Predictmedix’s AI algorithms are constantly improving Predictmedix is dedicated to r

  13. Slide 13: Leading organizations adopting or testing Safe Entry Stations

    Leading organizations and healthcare facilities are adopting or testing Safe Entry Stations MGM Healthcare Paras Defence & Space ICFF Film Festival Hospitals Technologies Public Event Secure Design Facilities Optima Living Sparta Health Indian Oil Corporation Seniors Residences Healthcare Clinics Of

  14. Slide 14: Screening as a Service drives recurring revenue

    Screening as a Service (SaaS) Drives High-Margin, Recurring Revenue with Multi-Year Contracts Hardware Deployment Recurring SaaS Fee Multi-Year Contracts $3,500 – 12,000/Unit $1,000 – 3,000/month Our customers invest in our technology not as a reaction to COVID, but with the long-term understanding

  15. Slide 15: The biggest and best believe in our solutions

    The biggest and best believe in our solutions Tech Mahindra – India Tier-1 Predictmedix has signed Joint Paras Defence – India Tier-2 Venture agreements with Tech Mahindra, who will resell North American Resellers Predictmedix secured a reseller Predictmedix to their global client agreement with Par

  16. Slide 16: Mainstream, trade, and investor media

    Mainstream, trade, and investor media are actively pursuing Predictmedix for interviews and features. 16 CSE : PMED OTCQB : PMEDF

  17. Slide 17: Remote patient monitoring and telehealth platform

    Remote patient monitoring & telehealth platform for healthcare, LTC and employers Long Term Care (LTC) Clinical Research Large Scale and Retirement Residences Organizations (CRO) Employees Covid-19 has revealed the devastating Traditional methods of on-site monitoring Existing human resource platfor

  18. Slide 18: U.S. Patents have been filed

    Protecting our Technology in Key Global markets 6 U.S. PATENTS HAVE BEEN FILED IMPAIRMENT (1) INFECTIOUS DISEASE SYMPTOMS (1) MOBILE WELL-BEING (4) 19 CSE : PMED OTCQB : PMEDF

  19. Slide 19: Management team

    Sheldon Kales Dr. Rahul Kushwah Rakesh Malhotra Nandan Mishra Himanshu Ujjawal Rajiv Muradia CEO COO CFO Co-AI Lead Singh VP, Technology Co-AI Lead § Expertise in operations, § PhD, Banting Fellow § CPA designation in § Artificial Intelligence § Mobile Wellbeing business strategy and (one of 23 glob

  20. Slide 20: Board of Directors

    Sheldon Kales Dr. Rahul Kushwah Ajit Kumar Tomas Sipos § Expertise in operations, business § PhD, Banting Fellow § Seasoned healthcare § Seasoned investment banker strategy and capital markets business leader § Developed world’s first genetic § Has held several senior positions, § Held leadership ro

  21. Slide 21: Advisory Board

    Advisory MSc, PhD MBBS, MS, DNB Board § Neurosurgeon with over 34 years’ experience in § One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private § Sugita Fellow from Nagoya University, Japan

  22. Slide 22: AI powered technologies positioned to eliminate need for biologics

    There is a growing need for rapid, mass, early stage § Proof of Efficacy: Independent Clinical Validation screening for governments, healthcare and employers. § Expand Revenue Base: Large scale commercial rollouts in North America, Europe and India, currently in discussion phases We also see that th

  23. Slide 23: Corporate information and investor relations

    CSE : PMED OTCQB : PMEDF PREDICTMEDIX.COM CORPORATE INFORMATION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 INVESTOR RELATIONS Lucas A. Zimmerman Director – MZ North America (949) 259-4987 PMEDF@mzgroup.us

Predictmedix — Investor Presentation (March 2022) on 6ix